Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUAK1 | O60285 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23634808 | 1.00 | NUAK1 (0.42) | NUAK1CRBNKDM4EALDH1A1DDB1 | |
| SCHEMBL23634844 | 1.00 | NUAK1 (0.42) | NUAK1CRBNKDM4EALDH1A1DDB1 | |
| SCHEMBL23635011 | 0.95 | CRBN (0.42) | NUAK1CRBNDDB1SIGMAR1PARP1 | |
| SCHEMBL23634906 | 0.95 | CRBN (0.42) | NUAK1CRBNDDB1SIGMAR1PARP1 | |
| SCHEMBL23635013 | 0.95 | CRBN (0.42) | NUAK1CRBNDDB1SIGMAR1PARP1 | |
| SCHEMBL23634843 | 0.90 | PDE3B (0.41) | CRBNKDM4EALDH1A1 | |
| SCHEMBL23634962 | 0.90 | CRBN (0.39) | NUAK1CRBNDDB1SIGMAR1POLB | |
| SCHEMBL23634864 | 0.90 | PDE3B (0.41) | CRBNKDM4EALDH1A1 | |
| SCHEMBL23634902 | 0.90 | PDE3B (0.41) | CRBNKDM4EALDH1A1 | |
| SCHEMBL23634893 | 0.89 | CRBN (0.43) | CRBNDDB1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | CRBN, CLNS1A, ADRM1 | NUAK1 2284/4885CRBN 1/4885KDM4E 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.